Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBI-07343
- Development stage
- Preclinical
- Lead developer
- Salud Integral
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
PBI-07343 is an investigational botanical extract derived from *Nerium oleander* developed by Phoenix Biotechnology and Salud Integral. It belongs to a family of oleander-based products (including ANVIRZEL, PBI-05204, and PBI-06150) that contain the cardiac glycoside oleandrin as a primary active component. PBI-07343 has been evaluated in preclinical safety and toxicology studies in animals, demonstrating a safe dosing range. Like other *Nerium oleander* extracts, its mechanism of action is primarily mediated by oleandrin, which selectively binds to and inhibits the Na+/K+-transporting ATPase (specifically targeting the alpha-3 subunit, ATP1A3, which is overexpressed in malignant cells). This inhibition leads to increased intracellular calcium levels, mitochondrial cytochrome C release, and caspase-dependent apoptosis, making it a potential therapeutic candidate for oncology applications.
- Other names
- Nerium oleander extract PBI-07343
02
Targets
ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1)ATP1A2 (Na+/K+-ATPase alpha-2)ATP1A3 (Na+/K+-ATPase alpha-3)
Beyond the preview
Go deeper on PBI-07343.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBI-07343.